|
| Status |
Public on Oct 24, 2013 |
| Title |
100µM zebularine, DU-145, biological rep 3 |
| Sample type |
RNA |
| |
|
| Source name |
DU-145 cells, 100µM zebularine, 216hours
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: DU-145
cell type: prostate cancer cell line
treatment: 100µM zebularine
time: 216 hrs
|
| Treatment protocol |
Cell seeding (day0), treatment start (24 hours later, day1), medium change and splitting of cells on day3 and day6.
|
| Growth protocol |
Monolayer cell culture (RPMI-1640 + 10%FCS) in the presence (100µM) or absence of Zebularine (SIGMA, cat. no. Z4775).
|
| Extracted molecule |
total RNA |
| Extraction protocol |
miRNeasy Mini Kit Qiagen (Cat. No.217004) total RNA extraction was done according to manufacturer's instructions, QC by AGILENT Bioanalyzer (only RIN >8.0 used).
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 300 ng total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).
|
| |
|
| Hybridization protocol |
Following fragmentation, cRNAs were hybridized for 16 hr at 45C on GeneChip Human Gene 1.0 ST Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
|
| Scan protocol |
GeneChips were scanned on the GeneChip Scanner 3000 G7.
|
| Description |
HK_26_DU_145_treat_3
ATCC No.: HTB-81
|
| Data processing |
The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100.
|
| |
|
| Submission date |
Oct 23, 2013 |
| Last update date |
Jan 24, 2014 |
| Contact name |
Hans G Krause |
| E-mail(s) |
hans.krause@charite.de
|
| Organization name |
Charité - Universitätsmedizin Berlin
|
| Department |
Klinik für Urologie
|
| Street address |
Charitéplatz 1
|
| City |
Berlin |
| ZIP/Postal code |
10117 |
| Country |
Germany |
| |
|
| Platform ID |
GPL10739 |
| Series (1) |
| GSE51629 |
Treatment of prostate cancer cell lines DU-145 and LNCaP with zebularine |
|
